Leading listed companies that produce Azivudine:
1. Tuoxin Pharmaceutical 301089: leading Azivudine stock.
The company’s anti-HIV products that have passed technical review include Azivudine API, which is jointly developed.
2. Xinhua Pharmaceutical 000756: leading Azivudine stock.
Signed a "Strategic Cooperation Agreement" with Real Biotechnology, agreeing that the company will be the manufacturer and distributor of its Azivudine and other products in China and other countries agreed by both parties. Azvudine, which is in the hands of real organisms, is a COVID-19 oral drug that has attracted widespread public attention recently. It is also one of the fastest-growing COVID-19 oral drugs currently under development in China.
Other Azivudine concept stocks include:
1. Hanyu Pharmaceutical.
2. Shanhe Pharmaceutical: The stock price has increased by 7.19% in the past 7 days, and the stock price will fall by -50.4% in 2022.
3. China Resources Double Crane: In the past 7 trading days, China Resources Double Crane has increased by 22.23%, and its total market value in 2022 has increased by 54.83%.
4. Shengjitang: In the past 7 trading days, Shengjitang fell by 4.23%, and its total market value fell by 4.23%.
Azvudine, also known as Azvudine, was invented by Professor Chang Junbiao, Henan Real Biotechnology Co., Ltd., Zhengzhou University, Henan Normal University, and High-Tech Research Center of Henan Academy of Sciences* **Same as R&D. It is an HIV reverse transcriptase (RT) inhibitor and is a new generation of AIDS treatment drugs that is advanced in the world and the first in China.
After Azivudine was found to be effective against the new coronavirus in February 2020, it was approved by the State Food and Drug Administration to conduct a phase III clinical trial against the new coronavirus in April 2020. In July 2021, Azivudine, an anti-HIV drug, was approved for marketing. It is the world's first dual-target innovative anti-AIDS drug.
On July 25, 2022, the State Food and Drug Administration issued an emergency conditional approval of Henan Real Biotechnology Co., Ltd.’s application for registration of Azfudine Tablets for the treatment of new coronavirus.